Short Interest in The Oncology Institute, Inc. (NASDAQ:TOI) Declines By 22.8%

The Oncology Institute, Inc. (NASDAQ:TOI) was the target of a large decline in short interest in September. As of September 15th, there was short interest totalling 233,000 shares, a decline of 22.8% from the August 31st total of 301,700 shares. Based on an average trading volume of 131,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 0.7% of the company’s stock are short sold.

Oncology Institute Stock Up 3.4 %

Shares of NASDAQ TOI traded up $0.01 during mid-day trading on Friday, hitting $0.31. 96,961 shares of the stock traded hands, compared to its average volume of 147,755. The company has a market cap of $23.05 million, a price-to-earnings ratio of -0.37 and a beta of 0.61. The stock has a fifty day moving average price of $0.40 and a 200-day moving average price of $0.73. Oncology Institute has a 52 week low of $0.27 and a 52 week high of $2.66. The company has a debt-to-equity ratio of 3.08, a quick ratio of 2.99 and a current ratio of 3.31.

Oncology Institute (NASDAQ:TOI) last announced its earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.07). The business had revenue of $98.58 million for the quarter, compared to the consensus estimate of $103.31 million. Oncology Institute had a negative net margin of 18.86% and a negative return on equity of 136.63%. During the same quarter last year, the firm posted ($0.19) EPS.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TOI. Nwam LLC bought a new position in Oncology Institute in the 1st quarter valued at approximately $44,000. Quattro Financial Advisors LLC bought a new position in shares of Oncology Institute during the first quarter valued at $88,000. Kent Lake Capital LLC boosted its position in shares of Oncology Institute by 9.4% during the first quarter. Kent Lake Capital LLC now owns 1,186,713 shares of the company’s stock valued at $1,875,000 after buying an additional 101,542 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Oncology Institute by 142.3% in the 2nd quarter. Renaissance Technologies LLC now owns 339,400 shares of the company’s stock worth $156,000 after buying an additional 199,300 shares in the last quarter. Finally, FourWorld Capital Management LLC bought a new stake in Oncology Institute in the 1st quarter worth about $396,000. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.